Technical Analysis for AKTX - Akari Therapeutics Plc

Grade Last Price % Change Price Change
grade D 1.94 0.52% 0.01
AKTX closed up 0.52 percent on Friday, September 20, 2019, on 13 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical AKTX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
50 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish 0.52%
50 DMA Support Bullish 0.52%
50 DMA Support Bullish 1.04%

Older signals for AKTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.
Medicine Biopharmaceutical Medical Specialties Organ Systems Rare Diseases Autoimmunity Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Complement System Sjögren's Syndrome
Is AKTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.2
52 Week Low 1.56
Average Volume 1,334,433
200-Day Moving Average 2.3237
50-Day Moving Average 1.9146
20-Day Moving Average 1.9005
10-Day Moving Average 1.94
Average True Range 0.1876
ADX 38.79
+DI 29.872
-DI 11.9572
Chandelier Exit (Long, 3 ATRs ) 1.8872
Chandelier Exit (Short, 3 ATRs ) 2.1778
Upper Bollinger Band 2.1034
Lower Bollinger Band 1.6976
Percent B (%b) 0.6
BandWidth 21.352276
MACD Line 0.0084
MACD Signal Line 0.0033
MACD Histogram 0.0052
Fundamentals Value
Market Cap 22.84 Million
Num Shares 11.8 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -0.97
Price-to-Sales 0.00
Price-to-Book 2.11
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.08
Resistance 3 (R3) 2.07 2.02 2.05
Resistance 2 (R2) 2.02 1.99 2.02 2.04
Resistance 1 (R1) 1.98 1.96 2.00 1.99 2.04
Pivot Point 1.93 1.93 1.94 1.93 1.93
Support 1 (S1) 1.89 1.90 1.91 1.90 1.84
Support 2 (S2) 1.84 1.87 1.84 1.84
Support 3 (S3) 1.80 1.84 1.83
Support 4 (S4) 1.81